PharmaBlock Sciences Nanjing Inc
SZSE:300725

Watchlist Manager
PharmaBlock Sciences Nanjing Inc Logo
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Watchlist
Price: 35.76 CNY 1.02% Market Closed
Market Cap: 7.1B CNY
Have any thoughts about
PharmaBlock Sciences Nanjing Inc?
Write Note

PharmaBlock Sciences Nanjing Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

PharmaBlock Sciences Nanjing Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Current Portion of Long-Term Debt
ÂĄ204.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Current Portion of Long-Term Debt
ÂĄ4.2B
CAGR 3-Years
625%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Current Portion of Long-Term Debt
ÂĄ27.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
12%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Current Portion of Long-Term Debt
ÂĄ36.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Current Portion of Long-Term Debt
ÂĄ68.7m
CAGR 3-Years
-58%
CAGR 5-Years
-40%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Current Portion of Long-Term Debt
ÂĄ179.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PharmaBlock Sciences Nanjing Inc
Glance View

Market Cap
7.1B CNY
Industry
Pharmaceuticals

PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.

Intrinsic Value
54.21 CNY
Undervaluation 34%
Intrinsic Value
Price

See Also

What is PharmaBlock Sciences Nanjing Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
204.8m CNY

Based on the financial report for Sep 30, 2024, PharmaBlock Sciences Nanjing Inc's Current Portion of Long-Term Debt amounts to 204.8m CNY.

What is PharmaBlock Sciences Nanjing Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 1Y
-12%

Over the last year, the Current Portion of Long-Term Debt growth was -12%.

Back to Top